Tradestie Institutional Equity Comparison Engine

BLTE vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BLTE Overall Edge

BLTE Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Belite Bio, Inc American Depositary Shares (BLTE) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, BLTE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, BLTE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BLTE N/M vs BHST N/M Fwd P/E
Growth & Margin Winner BLTE
Op Margin 0.0% vs -18.0% ยท YoY +0.0% vs +3.8%
Momentum & Technical Winner BLTE
1Y +5.8% vs -79.4% ยท 52W Pos 23% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BLTE NASDAQ
Belite Bio, Inc American Depositary Shares
Pharmaceutical Preparations
$127.38
-15.65% 1D
Market Cap $5.4B
1M Return -15.23%
1Y Return +5.83%
Forward P/E N/M
Unified AI Score
39.7 / 100 SELL
Tech 23.0 Fund 42.0 Flow 50.0 Mom 60.0
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BLTE +5.83% BHST -79.4% Spread: +85.23 pp (BLTE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BLTE TTM Op. Margin: 0.0% BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLTE vs BHST. Trailing 12-month operating profitability (BLTE 0.0% vs BHST -18.0%) and valuation multiples (BLTE N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BLTE (6) vs BHST (2)
Institutional Metric BLTE BHST Criterion Row Winner
Market Capitalization Scale $5.4B $29.9M Larger Scale BLTE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +3.8% Higher Growth BHST
Operating Margin (TTM) Profitability 0.0% -18.0% Higher Margin BLTE
Net Profit Margin Profitability 0.0% -31.2% Higher Margin BLTE
Return on Equity (ROE) Capital Efficiency -21.2% -142.5% Higher ROE BLTE
52-Week Range Position Momentum 23% ($106โ€“$200) 6% ($1โ€“$7) Stronger Trend BLTE
Beta / 30D Volatility Risk Regime 1.31ฮฒ ยท 71% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk BLTE
Unified Institutional Score Composite Signal 39.7 / 100 (SELL) 58.2 / 100 (HOLD) Higher Composite BHST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BLTE vs BHST Buy Guide
BLTE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BLTE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BLTE nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.